Global Outsourcing: A Roundtable of Contract Manufacturers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Global Outsourcing: A Roundtable of Contract Manufacturers
Leading contract manufacturing organizations share their views on the current and future market dynamics shaping pharmaceutical outsourcing.


Pharmaceutical Technology



COMSTOCK IMAGES/GETTY IMAGES
The elongation of the pharmaceutical supply chain is an important influence on the current and future state of outsourcing. To keep pace with changing requirements of sponsor companies, contract manufacturing organizations (CMOs) have broadened geographically to create a global footprint. Several Asia-based CMOs recently invested in manufacturing and development operations in North America and Western Europe, and select Western CMOs have similarly strengthened their positions in Asia. To gain a perspective on the critical issues, challenges, and factors affecting outsourcing, Pharmaceutical Technology conducted a roundtable of leading CMOs that have pursued this strategy in primary (i.e., intermediates and active pharmaceutical ingredients) and secondary (i.e., finished drug product) manufacturing and development.

Participants in the roundtable were: Steve Hagen, vice-president of pharmaceutical development and manufacturing at AMRI (Albany, NY); Tim Tyson, CEO of Aptuit (Greenwich, CT); David Andrews, sales director at Dishman USA, and Christian Dowdeswell, sales director at Dishman Europe, part of Dishman Pharmaceuticals and Chemicals (Ahmedabad, Gujarat, India); Abhijit Mukherjee, president and head of pharmaceutical services and active ingredients at Dr. Reddy's Laboratories (Hyderabad, Andhra Pradesh, India); N. Santhanam, chief operating officer of Piramal Healthcare (Mumbai, India); Terry Novak, president of North American operations and chief commercial officer at Patheon (Toronto); and Ed Roullard, vice-president of SAFC Supply Solutions, part of SAFC (St. Louis, MO).

Cost differentials between Western and Asian suppliers

PharmTech» CMOs in Asia have generally been perceived as being able to offer lower costs compared with their counterparts in North America and Europe, but rising costs for labor, transportation, and energy have eroded some of this differential. What cost pressures have arisen in the market and what has been their effect on the competitive dynamics of outsourcing to Asia?


Figure 1
»Mukherjee (Dr. Reddy's): The custom-manufacturing landscape has become extremely competitive around the world. The cost differential between India and the West still exists to an extent, but the West has become far more competitive with respect to price by embracing process and manufacturing efficiency, driving the cost out of their production. They are accomplishing this by utilizing a global network of suppliers for their materials as well as achieving operational efficiencies. Today, the selection of a supplier is no longer driven by pricing, but rather by the total service offering. Service providers from Asia need to demonstrate their technical sophistication and manufacturing efficiency in a way that was not required in the past. Cost is no longer the single competitive advantage for any CMO. To be successful, cost along with strong quality, safety, health, environmental, sourcing, and supply-chain programs must be evident.

»Roullard (SAFC): Adam Smith's theory of the "invisible hand" is actively at work between the Western and Asia marketplaces. Costs have definitely increased in Asia, driven by many factors, the most significant being an increase in labor costs for chemists and engineers. Labor costs in Asia continue to be lower than those of Western suppliers, but the gap is closing due to shifting demand, competition for resources, and the spread of relative wealth as these economies develop. The existing differential has customers setting explicit strategies for utilization of Asian outsourcing partners for projects requiring commoditized capability. And, those in the West with common technologies, common quality, and common supply-chain capabilities are feeling the most competitive pressure. However, those companies that are able to provide unique technologies or provide supply-chain security for critical raw materials are able to differentiate to an extent that ensures, at worst, mid-term viability as a value-added supplier.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
26%
Attracting a skilled workforce
29%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
Source: Pharmaceutical Technology,
Click here